Form 4: Edwards Lifesciences CFO Executes Option, Sells Shares

Edwards Lifesciences' Chief Financial Officer, Scott B. Ullem, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Scott B. Ullem, CVP and Chief Financial Officer of Edwards Lifesciences Corp (EW), reported transactions on November 10, 2025.
• Ullem exercised employee stock options to acquire 13,000 shares of common stock at an exercise price of $59.2567 per share.
• Following the option exercise, Ullem sold a total of 13,000 shares of common stock in two separate transactions.
• The first sale involved 2,974 shares at a weighted average price of $83.2999 per share.
• The second sale involved 10,026 shares at a weighted average price of $83.0201 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on July 29, 2025.
• After these transactions, Ullem directly beneficially owns 39,898 shares of common stock and indirectly owns 266,318 shares through a trust.
• Ullem also directly beneficially owns 46,700 employee stock options (rights to acquire common stock).

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 plan. This is generally considered neutral as it's a planned event for personal financial management rather than a signal of company performance or outlook.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not opportunistic sale.
• The exercise of options suggests the options were in-the-money, reflecting a gain for the insider.

Negatives

• The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted by some investors as a lack of conviction, though it is often for personal financial planning or diversification.

Risks

• No specific company-related risks are disclosed in this Form 4 filing. However, significant insider selling, if not part of a 10b5-1 plan or for a clear reason, can sometimes be perceived as a potential negative signal by the market.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025.
• The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

This filing reports routine insider trading activity and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock ownership and trading activity, which can influence investor sentiment regarding management's alignment and confidence.

Next Steps

• The Reporting Person has undertaken to provide full information regarding the number of shares and prices at which the transactions were effected, upon request by the SEC staff, the Issuer, or a security holder of the Issuer.

Key Dates

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, Stock Options, Share Sale, Executive Compensation, Scott B. Ullem, CFO, Rule 10b5-1 Plan